{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T21:15:51Z","timestamp":1757625351223,"version":"3.44.0"},"reference-count":63,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,8,21]],"date-time":"2025-08-21T00:00:00Z","timestamp":1755734400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,8,21]],"date-time":"2025-08-21T00:00:00Z","timestamp":1755734400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Discov Onc"],"DOI":"10.1007\/s12672-025-03443-w","type":"journal-article","created":{"date-parts":[[2025,8,21]],"date-time":"2025-08-21T01:13:34Z","timestamp":1755738814000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The role of angiotensinogen, angiotensin II receptor type I and type II receptor polymorphisms (AGTR2 rs11091046, AGT rs699, AGTR1 rs5186, and AGT rs4762) in multiple myeloma"],"prefix":"10.1007","volume":"16","author":[{"given":"Istemi","family":"Serin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasemin","family":"Oyaci","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sacide","family":"Pehlivan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elif","family":"Ertas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fatma Ceren","family":"Tuncel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mustafa","family":"Pehlivan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,8,21]]},"reference":[{"key":"3443_CR1","doi-asserted-by":"publisher","first-page":"1802","DOI":"10.1002\/ajh.27422","volume":"99","author":"SV Rajkumar","year":"2024","unstructured":"Rajkumar SV. Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management. Am J Hematol. 2024;99:1802\u201324. https:\/\/doi.org\/10.1002\/ajh.27422.","journal-title":"Am J Hematol"},{"key":"3443_CR2","doi-asserted-by":"publisher","first-page":"5611","DOI":"10.1038\/sj.onc.1204641","volume":"20","author":"PL Bergsagel","year":"2001","unstructured":"Bergsagel PL, Kuehl WM. Chromosome translocations in multiple myeloma. Oncogene. 2001;20:5611\u201322. https:\/\/doi.org\/10.1038\/sj.onc.1204641.","journal-title":"Oncogene"},{"key":"3443_CR3","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/j.hoc.2023.12.010","volume":"38","author":"F Maura","year":"2024","unstructured":"Maura F, Bergsagel PL. Molecular pathogenesis of multiple myeloma: clinical implications. Hematol Oncol Clin North Am. 2024;38:267\u201379. https:\/\/doi.org\/10.1016\/j.hoc.2023.12.010.","journal-title":"Hematol Oncol Clin North Am"},{"key":"3443_CR4","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1007\/s00277-020-03979-7","volume":"99","author":"P Zhang","year":"2020","unstructured":"Zhang P, Liu B. Genetic polymorphisms and multiple myeloma risk: a meta-analysis. Ann Hematol. 2020;99:1017\u201324. https:\/\/doi.org\/10.1007\/s00277-020-03979-7.","journal-title":"Ann Hematol"},{"key":"3443_CR5","doi-asserted-by":"publisher","first-page":"1316","DOI":"10.1038\/bmt.2009.335","volume":"45","author":"C Dumontet","year":"2010","unstructured":"Dumontet C, Landi S, Reiman T, Perry T, Plesa A, Bellini I, Barale R, Pilarski LM, Troncy J, Tavtigian S, Gemignani F. Genetic polymorphisms associated with outcome in multiple myeloma patients receiving high-dose Melphalan. Bone Marrow Transpl. 2010;45:1316\u201324. https:\/\/doi.org\/10.1038\/bmt.2009.335.","journal-title":"Bone Marrow Transpl"},{"key":"3443_CR6","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1016\/S0006-291X(02)00496-5","volume":"294","author":"M Fujita","year":"2002","unstructured":"Fujita M, Hayashi I, Yamashina S, Itoman M, Majima M. Blockade of angiotensin AT1a receptor signaling reduces tumor growth, angiogenesis, and metastasis. Biochem Biophys Res Commun. 2002;294:441\u20137. https:\/\/doi.org\/10.1016\/S0006-291X(02)00496-5.","journal-title":"Biochem Biophys Res Commun"},{"key":"3443_CR7","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1677\/joe.0.1730315","volume":"173","author":"A Muscella","year":"2002","unstructured":"Muscella A, Greco S, Elia MG, Storelli C, Marsigliante S. Angiotensin II stimulation of Na+\/K\u2009+\u2009ATPase activity and cell growth by calcium-independent pathway in MCF-7 breast cancer cells. J Endocrinol. 2002;173:315\u201323. https:\/\/doi.org\/10.1677\/joe.0.1730315.","journal-title":"J Endocrinol"},{"key":"3443_CR8","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1172\/JCI16645","volume":"112","author":"K Egami","year":"2003","unstructured":"Egami K, Murohara T, Shimada T, Sasaki K, Shintani S, Sugaya T, Ishii M, Akagi T, Ikeda H, Matsuishi T, Imaizumi T. Role of host angiotensin II type 1 receptor in tumor angiogenesis and growth. J Clin Invest. 2003;112:67\u201375. https:\/\/doi.org\/10.1172\/JCI16645.","journal-title":"J Clin Invest"},{"key":"3443_CR9","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1111\/j.1365-2796.2008.01981.x","volume":"264","author":"F Fyhrquist","year":"2008","unstructured":"Fyhrquist F, Saijonmaa O. Renin-angiotensin system revisited. J Intern Med. 2008;264:224\u201336. https:\/\/doi.org\/10.1111\/j.1365-2796.2008.01981.x.","journal-title":"J Intern Med"},{"key":"3443_CR10","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1177\/1470320313496858","volume":"16","author":"T Wegman-Ostrosky","year":"2015","unstructured":"Wegman-Ostrosky T, Soto-Reyes E, Vidal-Mill\u00e1n S, S\u00e1nchez-Corona J. The renin-angiotensin system Meets the hallmarks of cancer. J Renin Angiotensin Aldosterone Syst. 2015;16:227\u201333. https:\/\/doi.org\/10.1177\/1470320313496858.","journal-title":"J Renin Angiotensin Aldosterone Syst"},{"key":"3443_CR11","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1038\/bjc.1998.145","volume":"77","author":"SI Hii","year":"1998","unstructured":"Hii SI, Nicol DL, Gotley DC, Thompson LC, Green MK, Jonsson JR. Captopril inhibits tumour growth in a xenograft model of human renal cell carcinoma. Br J Cancer. 1998;77:880\u20133. https:\/\/doi.org\/10.1038\/bjc.1998.145.","journal-title":"Br J Cancer"},{"key":"3443_CR12","doi-asserted-by":"publisher","first-page":"150","DOI":"10.3389\/fendo.2013.00150","volume":"4","author":"D Herr","year":"2013","unstructured":"Herr D, Bekes I, Wulff C. Local Renin-Angiotensin system in the reproductive system. Front Endocrinol (Lausanne). 2013;4:150. https:\/\/doi.org\/10.3389\/fendo.2013.00150.","journal-title":"Front Endocrinol (Lausanne)"},{"key":"3443_CR13","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1172\/JCI14276","volume":"109","author":"G Nguyen","year":"2002","unstructured":"Nguyen G, Delarue F, Burckl\u00e9 C, Bouzhir L, Giller T, Sraer JD. Pivotal role of the Renin\/prorenin receptor in angiotensin II production and cellular responses to Renin. J Clin Invest. 2002;109:1417\u201327. https:\/\/doi.org\/10.1172\/JCI14276.","journal-title":"J Clin Invest"},{"key":"3443_CR14","doi-asserted-by":"publisher","first-page":"280","DOI":"10.3181\/00379727-196-43189","volume":"196","author":"L Chen","year":"1991","unstructured":"Chen L, Re RN, Prakash O, Mondal D. Angiotensin-converting enzyme Inhibition reduces neuroblastoma cell growth rate. Proc Soc Exp Biol Med. 1991;196:280\u20133. https:\/\/doi.org\/10.3181\/00379727-196-43189.","journal-title":"Proc Soc Exp Biol Med"},{"key":"3443_CR15","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/s0014-5793(01)02377-8","volume":"495","author":"Y Fujimoto","year":"2001","unstructured":"Fujimoto Y, Sasaki T, Tsuchida A, Chayama K. Angiotensin II type 1 receptor expression in human pancreatic cancer and growth Inhibition by angiotensin II type 1 receptor antagonist. FEBS Lett. 2001;495:197\u2013200. https:\/\/doi.org\/10.1016\/s0014-5793(01)02377-8.","journal-title":"FEBS Lett"},{"key":"3443_CR16","first-page":"1139","volume":"2","author":"H Uemura","year":"2003","unstructured":"Uemura H, Ishiguro H, Nakaigawa N, Nagashima Y, Miyoshi Y, Fujinami K, Sakaguchi A, Kubota Y. Angiotensin II receptor blocker shows antiproliferative activity in prostate cancer cells: a possibility of tyrosine kinase inhibitor of growth factor. Mol Cancer Ther. 2003;2:1139\u201347.","journal-title":"Mol Cancer Ther"},{"key":"3443_CR17","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1002\/pros.10294","volume":"58","author":"G Ronquist","year":"2004","unstructured":"Ronquist G, Rodr\u00edguez LA, Ruig\u00f3mez A, Johansson S, Wallander MA, Frithz G, Sv\u00e4rdsudd K. Association between captopril, other antihypertensive drugs and risk of prostate cancer. Prostate. 2004;58:50\u20136. https:\/\/doi.org\/10.1002\/pros.10294.","journal-title":"Prostate"},{"key":"3443_CR18","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/S0140-6736(98)03228-0","volume":"352","author":"AF Lever","year":"1998","unstructured":"Lever AF, Hole DJ, Gillis CR, McCallum IR, McInnes GT, MacKinnon PL, Meredith PA, Murray LS, Reid JL, Robertson JW. Do inhibitors of angiotensin-I-converting enzyme protect against risk of cancer? Lancet. 1998;352:179\u201384. https:\/\/doi.org\/10.1016\/S0140-6736(98)03228-0.","journal-title":"Lancet"},{"key":"3443_CR19","doi-asserted-by":"publisher","first-page":"e93050","DOI":"10.1371\/journal.pone.0093050","volume":"9","author":"N Koyama","year":"2014","unstructured":"Koyama N, Nishida Y, Ishii T, Yoshida T, Furukawa Y, Narahara H. Telmisartan induces growth inhibition, DNA double-strand breaks and apoptosis in human endometrial cancer cells. PLoS ONE. 2014;9:e93050. https:\/\/doi.org\/10.1371\/journal.pone.0093050.","journal-title":"PLoS ONE"},{"key":"3443_CR20","first-page":"295","volume":"20","author":"K Funao","year":"2008","unstructured":"Funao K, Matsuyama M, Kawahito Y, Sano H, Chargui J, Touraine JL, Nakatani T, Yoshimura R. Telmisartan is a potent target for prevention and treatment in human prostate cancer. Oncol Rep. 2008;20:295\u2013300.","journal-title":"Oncol Rep"},{"key":"3443_CR21","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1016\/j.bbamcr.2016.03.010","volume":"1863","author":"E Oh","year":"2016","unstructured":"Oh E, Kim JY, Cho Y, An H, Lee N, Jo H, Ban C, Seo JH. Overexpression of angiotensin II type 1 receptor in breast cancer cells induces epithelial-mesenchymal transition and promotes tumor growth and angiogenesis. Biochim Biophys Acta. 2016;1863:1071\u201381. https:\/\/doi.org\/10.1016\/j.bbamcr.2016.03.010.","journal-title":"Biochim Biophys Acta"},{"key":"3443_CR22","doi-asserted-by":"publisher","first-page":"929979","DOI":"10.3389\/fbioe.2022.929979","volume":"10","author":"H Wang","year":"2022","unstructured":"Wang H, Cui Y, Gong H, Xu J, Huang S, Tang A. Suppression of AGTR1 induces cellular senescence in hepatocellular carcinoma through inactivating ERK signaling. Front Bioeng Biotechnol. 2022;10:929979. https:\/\/doi.org\/10.3389\/fbioe.2022.929979.","journal-title":"Front Bioeng Biotechnol"},{"key":"3443_CR23","doi-asserted-by":"publisher","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","volume":"17","author":"S Kumar","year":"2016","unstructured":"Kumar S, Paiva B, Anderson KC, Durie B, Landgren O, Moreau P, Munshi N, Lonial S, Blad\u00e9 J, Mateos MV, Dimopoulos M, Kastritis E, Boccadoro M, Orlowski R, Goldschmidt H, Spencer A, Hou J, Chng WJ, Usmani SZ, Zamagni E, Shimizu K, Jagannath S, Johnsen HE, Terpos E, Reiman A, Kyle RA, Sonneveld P, Richardson PG, McCarthy P, Ludwig H, Chen W, Cavo M, Harousseau JL, Lentzsch S, Hillengass J, Palumbo A, Orfao A, Rajkumar SV, Miguel JS, Avet-Loiseau H. International myeloma working group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol. 2016;17:e328\u201346. https:\/\/doi.org\/10.1016\/S1470-2045(16)30206-6.","journal-title":"Lancet Oncol"},{"key":"3443_CR24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.preghy.2019.08.006","volume":"18","author":"LM Procopciuc","year":"2019","unstructured":"Procopciuc LM, Nemeti G, Buzdugan E, Iancu M, Stamatian F, Caracostea G. Renin-angiotensin system gene variants and risk of early- and late-onset preeclampsia: A single center case-control study. Pregnancy Hypertens. 2019;18:1\u20138. https:\/\/doi.org\/10.1016\/j.preghy.2019.08.006.","journal-title":"Pregnancy Hypertens"},{"key":"3443_CR25","first-page":"137","volume":"10","author":"S Mottaghi","year":"2019","unstructured":"Mottaghi S, Azarpira N, Dehshahri A, Khalvati B, Namazi S. Evaluation of angiotensinogen M235T and T174M polymorphisms, demographic and clinical factors in New-Onset diabetes after liver transplantation in Iranian patients. Int J Organ Transpl Med. 2019;10:137\u201347.","journal-title":"Int J Organ Transpl Med"},{"key":"3443_CR26","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1007\/s10459-010-9222-y","volume":"15","author":"G Norman","year":"2010","unstructured":"Norman G. Likert scales, levels of measurement and the laws of statistics. Adv Health Sci Educ Theory Pract. 2010;15:625\u201332. https:\/\/doi.org\/10.1007\/s10459-010-9222-y.","journal-title":"Adv Health Sci Educ Theory Pract"},{"key":"3443_CR27","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1007\/s00404-015-3661-x","volume":"292","author":"F Beyazit","year":"2015","unstructured":"Beyazit F, Ayhan S, Celik HT, Gungor T. Assessment of serum Angiotensin- converting enzyme in patients with epithelial ovarian cancer. Arch Gynecol Obstet. 2015;292:415\u201320. https:\/\/doi.org\/10.1007\/s00404-015-3661-x.","journal-title":"Arch Gynecol Obstet"},{"key":"3443_CR28","doi-asserted-by":"publisher","first-page":"2619","DOI":"10.3892\/ijo.2016.3458","volume":"48","author":"K Domi\u0144 ska","year":"2016","unstructured":"Domi\u0144 ska K, Och\u0229dalski T, Kowalska K, Matysiak-Burzy\u0144 ska ZE, P\u0142uciennik E, Piastowska-Ciesielska AW. Interaction between angiotensin II and relaxin 2 in the progress of growth and spread of prostate cancer cells. Int J Oncol. 2016;48:2619\u201328. https:\/\/doi.org\/10.3892\/ijo.2016.3458.","journal-title":"Int J Oncol"},{"key":"3443_CR29","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.3892\/or.2016.4887","volume":"36","author":"M Nowakowska","year":"2016","unstructured":"Nowakowska M, Matysiak-Burzy\u0144ska Z, Kowalska K, P\u0142uciennik E, Domi\u0144ska K, Piastowska-Ciesielska AW. Angiotensin II promotes endometrial cancer cell survival. Oncol Rep. 2016;36:1101\u201310. https:\/\/doi.org\/10.3892\/or.2016.4887.","journal-title":"Oncol Rep"},{"key":"3443_CR30","doi-asserted-by":"publisher","first-page":"9110","DOI":"10.1002\/jcb.27174","volume":"119","author":"ZE Matysiak-Burzy\u0144 ska","year":"2018","unstructured":"Matysiak-Burzy\u0144 ska ZE, Nowakowska M, Domi\u0144 ska K, Kowalska K, P\u0142uciennik E, Piastowska-Ciesielska AW. Silencing of angiotensin receptor 1 interferes with angiotensin II oncogenic activity in endometrial cancer. J Cell Biochem. 2018;119:9110\u201321. 10.1002\/ jcb.27174.","journal-title":"J Cell Biochem"},{"key":"3443_CR31","doi-asserted-by":"publisher","first-page":"e3891","DOI":"10.1016\/j.urolonc.2014.11.022","volume":"339","author":"WF Ara\u00fajo","year":"2015","unstructured":"Ara\u00fajo WF, Naves MA, Ravanini JN, Schor N, Teixeira VPC. Renin- angiotensin system (RAS) Blockade attenuates growth and metastatic potential of renal cell carcinoma in mice. Urol Oncol Semin Orig Investig. 2015;339:e3891\u20137. https:\/\/doi.org\/10.1016\/j.urolonc.2014.11.022.","journal-title":"Urol Oncol Semin Orig Investig"},{"key":"3443_CR32","doi-asserted-by":"publisher","first-page":"5059","DOI":"10.3892\/ol.2017.6826","volume":"14","author":"P Sobczuk","year":"2017","unstructured":"Sobczuk P, Szczylik C, Porta C, Czarnecka AM. Renin angiotensin system deregulation as renal cancer risk factor (Review). Oncol Lett. 2017;14:5059\u201368. https:\/\/doi.org\/10.3892\/ol.2017.6826.","journal-title":"Oncol Lett"},{"key":"3443_CR33","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1111\/eos.12356","volume":"125","author":"EE Hinsley","year":"2017","unstructured":"Hinsley EE, de Oliveira CE, Hunt S, Coletta RD, Lambert DW. Angiotensin 1\u20137 inhibits angiotensin II-Stimulated head and neck cancer progression. Eur J Oral Sci. 2017;125:247\u201357. https:\/\/doi.org\/10.1111\/eos.12356.","journal-title":"Eur J Oral Sci"},{"key":"3443_CR34","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1158\/1535-7163.MCT-15-0448","volume":"15","author":"NA Alhakamy","year":"2016","unstructured":"Alhakamy NA, Ishiguro S, Uppalapati D, Berkland CJ. AT2R gene delivered by condensed polylysine complexes attenuates Lewis lung carcinoma after intravenous injection or intratracheal spray. Mol Cancer Ther. 2016;15:209\u201318. https:\/\/doi.org\/10.1158\/1535-7163.MCT-15-0448.","journal-title":"Mol Cancer Ther"},{"key":"3443_CR35","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/j.xphs.2016.08.023","volume":"106","author":"S Ishiguro","year":"2017","unstructured":"Ishiguro S, Alhakamy NA, Uppalapati D, Delzeit J, Berkland CJ, Tamura M. Combined local pulmonary and systemic delivery of AT2R gene by modified TAT peptide nanoparticles attenuates both murine and human lung carcinoma xenografts in mice. J Pharm Sci. 2017;106:385\u201394. https:\/\/doi.org\/10.1016\/j.xphs.2016.08.023.","journal-title":"J Pharm Sci"},{"key":"3443_CR36","doi-asserted-by":"publisher","first-page":"178","DOI":"10.4274\/tjh.galenos.2019.2018.0420","volume":"36","author":"B Saka","year":"2019","unstructured":"Saka B, Sayito\u011flu M, \u0130stemihan Z, Karan MA, Erten N, Do\u011fan \u00d6, \u00d6zbek U, Gen\u00e7 S, Ta\u015f\u00e7\u0131o\u011flu C, Kalayo\u011flu-Be\u015f\u0131\u015f\u0131k S. The role of the local bone marrow Renin-Angiotensin system in multiple myeloma. Turk J Haematol. 2019;36:178\u201385. https:\/\/doi.org\/10.4274\/tjh.galenos.2019.2018.0420.","journal-title":"Turk J Haematol"},{"key":"3443_CR37","doi-asserted-by":"publisher","first-page":"44","DOI":"10.3389\/fonc.2019.00044","volume":"9","author":"S Zmorzynski","year":"2019","unstructured":"Zmorzynski S, Szudy-Szczyrek A, Popek-Marciniec S, Korszen-Pilecka I, Wojcierowska-Litwin M, Luterek M, Chocholska S, Styk W, Swiderska-Ko\u0142acz G, Januszewska J, Mielnik M, Hus M, Filip AA. ACE insertion\/deletion polymorphism (rs4646994) is associated with the increased risk of multiple myeloma. Front Oncol. 2019;9:44. https:\/\/doi.org\/10.3389\/fonc.2019.00044.","journal-title":"Front Oncol"},{"key":"3443_CR38","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1172\/JCI114844","volume":"86","author":"B Rigat","year":"1990","unstructured":"Rigat B, Hubert C, Alhenc-Gelas F, Cambien F, Corvol P, Soubrier F. An insertion\/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels. J Clin Invest. 1990;86:1343\u20136. https:\/\/doi.org\/10.1172\/JCI114844.","journal-title":"J Clin Invest"},{"key":"3443_CR39","doi-asserted-by":"publisher","first-page":"e101502","DOI":"10.1371\/journal.pone.0101502","volume":"9","author":"S Chandra","year":"2014","unstructured":"Chandra S, Narang R, Sreenivas V, Bhatia J, Saluja D, Srivastava K. Association of angiotensin II type 1 receptor (A1166C) gene polymorphism and its increased expression in essential hypertension: a case-control study. PLoS ONE. 2014;9:e101502. https:\/\/doi.org\/10.1371\/journal.pone.0101502.","journal-title":"PLoS ONE"},{"key":"3443_CR40","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1177\/1470320315584096","volume":"16","author":"DX Liu","year":"2015","unstructured":"Liu DX, Zhang YQ, Hu B, Zhang J, Zhao Q. Association of AT1R polymorphism with hypertension risk: an update meta-analysis based on 28,952 subjects. J Renin Angiotensin Aldosterone Syst. 2015;16:898\u2013909. https:\/\/doi.org\/10.1177\/1470320315584096.","journal-title":"J Renin Angiotensin Aldosterone Syst"},{"key":"3443_CR41","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/0092-8674(92)90275-h","volume":"71","author":"X Jeunemaitre","year":"1992","unstructured":"Jeunemaitre X, Soubrier F, Kotelevtsev YV, Lifton RP, Williams CS, Charru A, Hunt SC, Hopkins PN, Williams RR, Lalouel JM, et al. Molecular basis of human hypertension: role of angiotensinogen. Cell. 1992;71:169\u201380. https:\/\/doi.org\/10.1016\/0092-8674(92)90275-h.","journal-title":"Cell"},{"key":"3443_CR42","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1530\/EC-15-0112","volume":"5","author":"KG Pringle","year":"2016","unstructured":"Pringle KG, Delforce SJ, Wang Y, Ashton KA, Proietto A, Otton G, Blackwell CC, Scott RJ, Lumbers ER. Renin-angiotensin system gene polymorphisms and endometrial cancer. Endocr Connect. 2016;5:128\u201335. https:\/\/doi.org\/10.1530\/EC-15-0112.","journal-title":"Endocr Connect"},{"key":"3443_CR43","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1161\/01.HYP.0000227932.13687.60","volume":"48","author":"ME Dickson","year":"2006","unstructured":"Dickson ME, Sigmund CD. Genetic basis of hypertension: revisiting angiotensinogen. Hypertension. 2006;48:14\u201320. https:\/\/doi.org\/10.1161\/01.HYP.0000227932.13687.60.","journal-title":"Hypertension"},{"key":"3443_CR44","doi-asserted-by":"publisher","first-page":"1765","DOI":"10.3390\/jcm9061765","volume":"9","author":"R Ria","year":"2020","unstructured":"Ria R, Melaccio A, Racanelli V, Vacca A. Anti-VEGF drugs in the treatment of multiple myeloma patients. J Clin Med. 2020;9:1765. https:\/\/doi.org\/10.3390\/jcm9061765.","journal-title":"J Clin Med"},{"key":"3443_CR45","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1055\/s-0040-1714933","volume":"12","author":"A Palta","year":"2020","unstructured":"Palta A, Kaur M, Tahlan A, Dimri K. Evaluation of angiogenesis in multiple myeloma by VEGF Immunoexpression and microvessel density. J Lab Physicians. 2020;12:38\u201343. https:\/\/doi.org\/10.1055\/s-0040-1714933.","journal-title":"J Lab Physicians"},{"key":"3443_CR46","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.1177\/147323000903700406","volume":"37","author":"M Sayitoglu","year":"2009","unstructured":"Sayitoglu M, Haznedaro\u011flu IC, Hatirnaz O, Erbilgin Y, Aksu S, Koca E, Adiguzel C, Bayik M, Akalin I, G\u00fclbas Z, Akay M, Unal A, Kaynar L, Ovali E, Yilmaz M, Yenerel M, Dagdas S, Ozet G, Ar C, Aydin Y, Soysal T, Durgun B, Ozcebe O, Tukun A, Ilhan O, Ozbek U. Effects of Imatinib mesylate on renin-angiotensin system (RAS) activity during the clinical course of chronic myeloid leukaemia. J Int Med Res. 2009;37:1018\u201328. https:\/\/doi.org\/10.1177\/147323000903700406.","journal-title":"J Int Med Res"},{"key":"3443_CR47","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1111\/j.1365-2141.2004.04998.x","volume":"126","author":"WB Strawn","year":"2004","unstructured":"Strawn WB, Richmond RS, Ann Tallant E, Gallagher PE, Ferrario CM. Renin-angiotensin system expression in rat bone marrow Haematopoietic and stromal cells. Br J Haematol. 2004;126:120\u20136. https:\/\/doi.org\/10.1111\/j.1365-2141.2004.04998.x.","journal-title":"Br J Haematol"},{"key":"3443_CR48","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1097\/00004872-199312050-00094","volume":"11","author":"M Crabos","year":"1993","unstructured":"Crabos M, Bertschin S, B\u00fchler FR, Rogg H, Ev\u00e9quoz D, Eberhard M, Erne P. Identification of AT1 receptors on human platelets and decreased angiotensin II binding in hypertension. J Hypertens Suppl. 1993;11:230\u20131.","journal-title":"J Hypertens Suppl"},{"key":"3443_CR49","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1634\/stemcells.18-4-287","volume":"18","author":"KE Rodgers","year":"2000","unstructured":"Rodgers KE, Xiong S, Steer R, diZerega GS. Effect of angiotensin II on hematopoietic progenitor cell proliferation. Stem Cells. 2000;18:287\u201394. https:\/\/doi.org\/10.1634\/stemcells.18-4-287.","journal-title":"Stem Cells"},{"key":"3443_CR50","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1080\/10245330290022160","volume":"7","author":"H Abali","year":"2002","unstructured":"Abali H, Haznedaroglu IC, Goker H, Celik I, Ozatli D, Koray Z, Caglar M. Circulating and local bone marrow renin-angiotensin system in leukemic hematopoiesis: preliminary evidences. Hematology. 2002;7:75\u201382. https:\/\/doi.org\/10.1080\/10245330290022160.","journal-title":"Hematology"},{"key":"3443_CR51","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1177\/1470320312437070","volume":"13","author":"M Albayrak","year":"2012","unstructured":"Albayrak M, Celebi H, Albayrak A, Sayilir A, Yesil Y, Balcik OS, Yokus O, Celik T. Elevated serum angiotensin converting enzyme levels as a reflection of bone marrow renin-angiotensin system activation in multiple myeloma. J Renin Angiotensin Aldosterone Syst. 2012;13:259\u201364. https:\/\/doi.org\/10.1177\/1470320312437070.","journal-title":"J Renin Angiotensin Aldosterone Syst"},{"key":"3443_CR52","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1007\/s13277-014-2713-3","volume":"36","author":"S Namazi","year":"2015","unstructured":"Namazi S, Sahebi E, Rostami-Yalmeh J, Jaberipour M, Razmkhah M, Hosseini A, Arabsolghar R. Effect of angiotensin receptor Blockade on prevention and reversion of tamoxifen-resistant phenotype in MCF-7 cells. Tumour Biol. 2015;36:893\u2013900. https:\/\/doi.org\/10.1007\/s13277-014-2713-3.","journal-title":"Tumour Biol"},{"key":"3443_CR53","doi-asserted-by":"publisher","first-page":"602","DOI":"10.3109\/00365521.2013.777776","volume":"48","author":"A Masamune","year":"2013","unstructured":"Masamune A, Hamada S, Kikuta K, Takikawa T, Miura S, Nakano E, Shimosegawa T. The angiotensin II type I receptor blocker Olmesartan inhibits the growth of pancreatic cancer by targeting stellate cell activities in mice. Scand J Gastroenterol. 2013;48:602\u20139. https:\/\/doi.org\/10.3109\/00365521.2013.777776.","journal-title":"Scand J Gastroenterol"},{"key":"3443_CR54","first-page":"4789","volume":"35","author":"S Tawinwung","year":"2015","unstructured":"Tawinwung S, Ninsontia C, Chanvorachote P. Angiotensin II increases cancer stem Cell-like phenotype in lung cancer cells. Anticancer Res. 2015;35:4789\u201397.","journal-title":"Anticancer Res"},{"key":"3443_CR55","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1007\/s10585-014-9635-8","volume":"31","author":"SL Koh","year":"2014","unstructured":"Koh SL, Ager EI, Costa PLN, Malcontenti-Wilson C, Muralidharan V, Christophi C. Blockade of the Renin-Angiotensin system inhibits growth of colorectal cancer liver metastases in the regenerating liver. Clin Exp Metastasis. 2014;31:395\u2013405. https:\/\/doi.org\/10.1007\/s10585-014-9635-8.","journal-title":"Clin Exp Metastasis"},{"key":"3443_CR56","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1530\/ERC-19-0314","volume":"26","author":"F Rasha","year":"2019","unstructured":"Rasha F, Ramalingam L, Gollahon L, Rahman RL, Rahman SM, Menikdiwela K, Moustaid-Moussa N. Mechanisms linking the renin-angiotensin system, obesity, and breast cancer. Endocr Relat Cancer. 2019;26:653\u201372. https:\/\/doi.org\/10.1530\/ERC-19-0314.","journal-title":"Endocr Relat Cancer"},{"key":"3443_CR57","doi-asserted-by":"publisher","first-page":"736361","DOI":"10.3389\/fendo.2021.736361","volume":"12","author":"M Almutlaq","year":"2021","unstructured":"Almutlaq M, Alamro AA, Alamri HS, Alghamdi AA, Barhoumi T. The effect of local Renin angiotensin system in the common types of cancer. Front Endocrinol (Lausanne). 2021;12:736361. https:\/\/doi.org\/10.3389\/fendo.2021.736361.","journal-title":"Front Endocrinol (Lausanne)"},{"key":"3443_CR58","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1186\/s12885-016-2955-0","volume":"16","author":"A Chari","year":"2016","unstructured":"Chari A, Mezzi K, Zhu S, Werther W, Felici D, Lyon AR. Incidence and risk of hypertension in patients newly treated for multiple myeloma: a retrospective cohort study. BMC Cancer. 2016;16:912. https:\/\/doi.org\/10.1186\/s12885-016-2955-0.","journal-title":"BMC Cancer"},{"key":"3443_CR59","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1038\/sj.thj.6200571","volume":"5","author":"T Buchler","year":"2005","unstructured":"Buchler T, Krejci M, Svobodnik A, Adam Z, Minarik J, Bacovsky J, Scudla V, Mayer J, Vorlicek J, Hajek R. Outcome of patients with multiple myeloma and hypertension treated with angiotensin-I-converting enzyme inhibitors during high-dose chemotherapy. Hematol J. 2005;5:559\u201364. https:\/\/doi.org\/10.1038\/sj.thj.6200571.","journal-title":"Hematol J"},{"key":"3443_CR60","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1038\/s41392-023-01705-z","volume":"8","author":"ME Bahar","year":"2023","unstructured":"Bahar ME, Kim HJ, Kim DR. Targeting the RAS\/RAF\/MAPK pathway for cancer therapy: from mechanism to clinical studies. Signal Transduct Target Ther. 2023;8:455. https:\/\/doi.org\/10.1038\/s41392-023-01705-z.","journal-title":"Signal Transduct Target Ther"},{"key":"3443_CR61","doi-asserted-by":"publisher","first-page":"1564","DOI":"10.1177\/1535370215576312","volume":"240","author":"C Wang","year":"2015","unstructured":"Wang C, Qian X, Sun X, Chang Q. Angiotensin II increases matrix metalloproteinase 2 expression in human aortic smooth muscle cells via AT1R and ERK1\/2. Exp Biol Med (Maywood). 2015;240:1564\u201371. https:\/\/doi.org\/10.1177\/1535370215576312.","journal-title":"Exp Biol Med (Maywood)"},{"key":"3443_CR62","doi-asserted-by":"publisher","unstructured":"Zanwar S, Novak J, Gonsalves WI, Howe M, Braggio E, Rajkumar SV, Binder M, Jevremovic D, Dasari S, Kumar SK. Extramedullary myeloma is genomically complex and characterized by Near-Universal MAPK pathway alterations. Blood Adv. 2025;bloodadvances2025016619. https:\/\/doi.org\/10.1182\/bloodadvances.2025016619.","DOI":"10.1182\/bloodadvances.2025016619"},{"key":"3443_CR63","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1634\/theoncologist.2019-0356","volume":"25","author":"MC Da Vi\u00e0","year":"2020","unstructured":"Da Vi\u00e0 MC, Solimando AG, Garitano-Trojaola A, Barrio S, Munawar U, Strifler S, Haertle L, Rhodes N, Teufel E, Vogt C, Lapa C, Beilhack A, Rasche L, Einsele H, Kort\u00fcm KM. CIC mutation as a molecular mechanism of acquired resistance to combined BRAF-MEK Inhibition in extramedullary multiple myeloma with central nervous system involvement. Oncologist. 2020;25:112\u20138. https:\/\/doi.org\/10.1634\/theoncologist.2019-0356.","journal-title":"Oncologist"}],"container-title":["Discover Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-025-03443-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12672-025-03443-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-025-03443-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,9]],"date-time":"2025-09-09T17:56:52Z","timestamp":1757440612000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12672-025-03443-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,21]]},"references-count":63,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3443"],"URL":"https:\/\/doi.org\/10.1007\/s12672-025-03443-w","relation":{},"ISSN":["2730-6011"],"issn-type":[{"type":"electronic","value":"2730-6011"}],"subject":[],"published":{"date-parts":[[2025,8,21]]},"assertion":[{"value":"8 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was conducted in compliance with the Declaration of Helsinki principles and received approval from the Istanbul University, Faculty of Medicine ethics committee (approval date and number: 29\/05\/2020\u201386529). Both patients and healthy controls provided written informed consent prior to participating in the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"was obtained in written form from all our patients to publish.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}],"article-number":"1588"}}